Effects of the α₂-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers.

@article{Hysek2012EffectsOT,
  title={Effects of the α₂-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers.},
  author={C{\'e}dric M. Hysek and Robin Brugger and Linda D. Simmler and Marcel Bruggisser and Massimiliano Donzelli and Eric Grouzmann and Marius C. Hoener and Matthias E Liechti},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2012},
  volume={340 2},
  pages={286-94}
}
The mechanism of action of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) involves the carrier-mediated and potentially vesicular release of monoamines. We assessed the effects of the sympatholytic α₂-adrenergic receptor agonist clonidine (150 μg p.o.), which inhibits the neuronal vesicular release of norepinephrine, on the cardiovascular and psychotropic response to MDMA (125 mg p.o.) in 16 healthy subjects. The study used a randomized, double-blind, placebo-controlled crossover design with… CONTINUE READING